Gradalis is developing and testing Vigil®, a fully personalized, patient-specific cancer immunotherapy that can be applied to virtually any cancer

Vigil is currently for people with

Ewing’s sarcoma

Our lead program focuses on the treatment of patients with recurrent or refractory Ewing’s sarcoma. Vigil utilizes the patient’s own cancer cells to create a fully personalized cancer immunotherapy with the goal to activate the patient’s own T-cells against their cancer cells.

We believe Vigil has several key features and advantages which differentiate it from other cancer immunotherapies:

1

We use the entire compliment of antigens present in patient’s cancer cells by using surgically removed fresh tumor tissue. The goal is to stimulate a robust immune response (T-cell activation) against a heterogeneous mix of cancer neoantigens specific to that patient.

2

With gene modification, we specifically down-regulate an immunosuppressive pathway of the cancer cells; and at the same time, up-regulate an immune stimulation function of those same cells.

When those cells are reintroduced back into the patient, these two modifications are designed to help activate the immune system to detect and kill any cancer cells that may remain locally and in circulation.

All together, the goal is to stimulate the existing components of the immune system with the intent to improve their anti-tumor responses. Vigil enhances specific functions that assist in cancer antigen recognition and dampen other functions that cancer cells often employ to evade the immune system.

We believe our approach of exploiting the patient's existing, highly-adapted immune system by presenting the entire neoantigen matrix and induced T-cell responses against their cancer has great promise

Vigil Clinical Trials

Find a location near me